```html

Klebsiella pneumoniae (Carbapenem‑Resistant)

Overview

Klebsiella pneumoniae is a gram‑negative rod‑shaped bacterium that normally lives in the human gut without causing disease. Certain strains, however, can become highly pathogenic and cause severe infections, especially when they acquire resistance to carbapenem antibiotics—a class that is often reserved for the most serious bacterial infections.

Who it affects: Carbapenem‑resistant Klebsiella pneumoniae (CR‑KP) most commonly affects:

• Patients in intensive care units (ICUs) or long‑term acute care facilities
• Individuals with invasive devices (ventilators, urinary catheters, central lines)
• People receiving broad‑spectrum antibiotics or chemotherapy
• Elderly adults, especially those with chronic illnesses (diabetes, chronic lung disease, renal failure)

Prevalence: According to the U.S. Centers for Disease Control and Prevention (CDC), CR‑KP accounted for approximately 10 % of all carbapenem‑resistant Enterobacteriaceae (CRE) infections in 2022. Worldwide, the World Health Organization (WHO) lists carbapenem‑resistant Klebsiella as a “critical priority” pathogen, noting outbreaks in Europe, Asia, and the Americas with mortality rates ranging from 30 % to 50 % in invasive infections.<sup>[1][2]</sup>

Symptoms

Symptoms vary depending on the site of infection. Below is a comprehensive list with brief descriptions.

Pneumonia (lung infection)

• Fever and chills
• Productive cough with thick, possibly blood‑tinged sputum
• Shortness of breath or rapid breathing
• Chest pain that worsens with deep breaths
• Confusion, especially in older adults

Urinary Tract Infection (UTI)

• Burning sensation during urination
• Frequent urge to urinate with little output
• Cloudy, foul‑smelling, or bloody urine
• Lower abdominal or back pain
• Fever in severe cases

Bloodstream Infection (Sepsis)

• High fever or low body temperature
• Rapid heart rate and breathing
• Altered mental status (confusion, lethargy)
• Low blood pressure (possible septic shock)
• Skin mottling or rash

Wound or Surgical Site Infection

• Redness, swelling, and warmth around the wound
• Pus or foul discharge
• Increasing pain at the site
• Fever

Other Possible Presentations

• Empyema (pus in the pleural space)
• Endophthalmitis (eye infection) – rare but documented in case reports
• Brain abscess or meningitis – extremely uncommon, usually in immunocompromised hosts

Causes and Risk Factors

How resistance develops

Klebsiella becomes carbapenem‑resistant primarily through acquisition of genes that encode carbapenemase enzymes (e.g., KPC, NDM, OXA‑48). These genes are often carried on plasmids—mobile DNA fragments that can transfer between bacteria, spreading resistance quickly.

Key risk factors

• Hospital exposure: ICU stay, surgery, or prolonged hospitalization
• Invasive devices: Endotracheal tubes, urinary catheters, central venous catheters, feeding tubes
• Antibiotic pressure: Recent use of carbapenems, third‑generation cephalosporins, or fluoroquinolones
• Immunosuppression: Cancer chemotherapy, organ transplantation, HIV/AIDS, corticosteroid therapy
• Chronic illnesses: Diabetes, chronic kidney disease, chronic obstructive pulmonary disease (COPD)
• Travel or healthcare abroad: Exposure to regions with high CRE prevalence

Diagnosis

Early and accurate diagnosis is essential because standard antibiotics often fail.

Microbiological testing

• Culture: Specimens from sputum, urine, blood, wound, or other sites are plated on selective media.
• Susceptibility testing: Automated systems (e.g., VITEK 2, MicroScan) or manual broth microdilution determine minimum inhibitory concentrations (MICs) for carbapenems and other agents.
• Carbapenemase detection:
  • Phenotypic tests such as the Modified Hodge Test or Carba NP
  • Molecular PCR assays targeting KPC, NDM, VIM, IMP, OXA‑48 genes

Additional diagnostic tools

• Chest X‑ray or CT scan for pneumonia
• Ultrasound or CT for intra‑abdominal or urinary infections
• Blood cultures (at least two sets) when sepsis is suspected
• Rapid multiplex panels (e.g., BioFire FilmArray) that can identify Klebsiella and resistance markers within hours

Treatment Options

Because CR‑KP resists many first‑line drugs, therapy usually involves a combination of older antibiotics, newer β‑lactam/β‑lactamase inhibitor combos, or investigational agents.

Recommended antimicrobial regimens (per 2023 IDSA guidance)

1. Polymyxins (colistin or polymyxin B) – often used as a backbone drug.
2. Combination therapy (recommended over monotherapy):
   • Polymyxin + meropenem (if MIC ≤ 8 µg/mL) + an aminoglycoside (e.g., amikacin) or
   • Polymyxin + tigecycline (for soft‑tissue or intra‑abdominal sources) or
   • Polymyxin + fosfomycin (especially for urinary infections)
3. Newer agents (when susceptibility is proven):
   • Ceftazidime‑avibactam (effective against KPC producers)
   • Meropenem‑vaborbactam (active against KPC)
   • Imipenem‑relebactam (limited data but promising)
   • Plazomicin (a next‑generation aminoglycoside)
4. Adjunctive measures:
   • Source control – removal of infected catheters, drainage of abscesses, debridement of wounds
   • Optimized dosing (extended or continuous infusion for β‑lactams) to maximize pharmacodynamic exposure

Supportive care

• Fluid resuscitation and vasopressors for septic shock (per Surviving Sepsis Guidelines)
• Oxygen therapy or mechanical ventilation for severe pneumonia
• Renal replacement therapy if nephrotoxic drugs cause acute kidney injury

Lifestyle and non‑pharmacologic measures

• Strict hand hygiene and contact precautions to prevent spread
• Nutrition optimization (high‑protein diet) to support immune function
• Smoking cessation – reduces lung damage and infection risk

Living with Klebsiella pneumoniae (Carbapenem‑Resistant)

Surviving a CR‑KP infection often means ongoing vigilance to prevent recurrence.

• Follow‑up appointments: Keep all infectious‑disease (ID) clinic visits; repeat cultures may be needed to confirm eradication.
• Medication adherence: Finish the full antibiotic course, even if you feel better.
• Device care: If you have a urinary catheter, central line, or feeding tube, ensure it is handled with sterile technique. Discuss with your provider the earliest safe removal.
• Vaccinations: Stay up‑to‑date on influenza, pneumococcal (PCV20 or PCV15 followed by PPSV23), and COVID‑19 vaccines to lower the risk of secondary infections.
• Home hygiene:
  • Disinfect high‑touch surfaces daily with EPA‑registered agents.
  • Wash hands with soap for at least 20 seconds after bathroom use, before meals, and after touching medical devices.
• Nutrition & hydration: Adequate protein (1.2–1.5 g/kg/day for recovering adults) and fluid intake help tissue healing.
• Physical activity: Gentle mobility as tolerated improves lung function and circulation; consult physical therapy for a tailored program.
• Psychological support: Infections with resistant organisms can cause anxiety. Consider counseling or support groups.

Prevention

The best strategy is to stop the bacteria from invading in the first place.

• Hand hygiene: Wash with soap and water or use alcohol‑based rubs before and after patient contact.
• Contact precautions in healthcare settings – gloves, gowns, and dedicated equipment for colonized or infected patients.
• Antibiotic stewardship: Only take antibiotics when prescribed; avoid “left‑over” pills.
• Environmental cleaning: Hospital surfaces, ventilator circuits, and bathroom fixtures should be cleaned with agents active against gram‑negative rods.
• Screening: Some institutions perform rectal swab screening for CRE on admission to high‑risk units.
• Device management: Remove catheters and lines as soon as they are no longer medically necessary.
• Travel precautions: If you travel to regions with known CRE outbreaks, practice extra hand hygiene and avoid unnecessary antibiotics.

Complications

Untreated or inadequately treated CR‑KP infection can lead to serious, sometimes fatal, outcomes.

• Septic shock – profound circulatory collapse requiring intensive care.
• Acute respiratory distress syndrome (ARDS) from severe pneumonia.
• Renal failure – often secondary to sepsis or nephrotoxic antibiotics.
• End‑organ damage – heart (myocarditis), liver (abscess), or brain (meningitis) in disseminated disease.
• Loss of limb or organ – due to necrotizing soft‑tissue infections.
• Prolonged hospitalization – increased risk of secondary infections (C. difficile, VRE).
• Increased mortality – reported 30‑50 % in bloodstream infections caused by CR‑KP.<sup>[3]</sup>

When to Seek Emergency Care

---

References:

1. World Health Organization. “Global priority list of antibiotic‑resistant bacteria to guide research, discovery, and development of new antibiotics.” 2017.
2. Centers for Disease Control and Prevention. “Carbapenem‑Resistant Enterobacteriaceae (CRE).” Updated 2023. https://www.cdc.gov/hai/organisms/klebsiella.html
3. U.S. Department of Health and Human Services. “Antibiotic Resistance Threats in the United States, 2019.” CDC.
4. Infectious Diseases Society of America. “Clinical Practice Guidelines for the Treatment of CRE Infections.” Clin Infect Dis. 2023.
5. Mayo Clinic. “Klebsiella pneumoniae infection.” 2024.

```